Abstract
Biological agents, particularly anti-Tumour Necrosis Factor (TNF)-α agents, have emerged as an effective treatment in patients with chronic inflammatory diseases. An association between anti-TNF-α antibodies and reactivation of latent tuberculosis infection (LTBI) has been established. Appropriate screening for TB infection has become mandatory before starting a treatment based on TNF-α inhibition. The objective was to determine the usefulness of IFN-γ release assays in diagnosing LTBI in patients with inflammatory rheumatic diseases scheduled for anti-TNF-α treatment. The study included 53 individuals with inflammatory rheumatism. All patients had a TST, a chest radiograph, QuantiFERON Gold In-Tube (QFN-G-IT) and T-SPOT.TB. To investigate the influence of non-tuberculous mycobacteria (NTM) infections on non-BCG-vaccinated patients, with a positive TST result and both negative IFN-γ assays, we performed an ex vivo ELISPOT, stimulating the cells separately with NTM sensitins. TST was positive in 7 cases, T-SPOT.TB in 11 and QFN-G-IT in 9 cases. Agreement between TST and T-SPOT.TB and QFN-G-IT was 77.35% (κ = 0.33 and κ = 0.40, respectively), and between both in vitro tests, it was 83.01% (κ = 0.57). Of the three patients with positive TST and negative T-SPOT.TB and QFN-G-IT, one positive ELISPOT result was obtained after stimulation with NTM sensitins. Positive TST, T-SPOT.TB and QFN-G-IT results were not affected by the immunosuppressive therapies. IFN-γ release assays are useful methods for avoiding TST false-positive results, but in those patients with a high risk of developing active TB and in the absence of predictive value studies in this specific kind of population for knowing how safe is the use of IGRAs alone, the combined use of TST and IFN-γ tests should be recommended in order to increase the overall number of LTBI diagnoses.
Similar content being viewed by others
References
Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P (2007) Crohn's disease: a review of current treatment with a focus on biologics. Drugs 67(17):2511–2537
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104
Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3(3):148–155
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa M (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772
Winthrop KL (2010) The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biological therapy. Int J Adv Rheumatol 8(2):43–52
Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17(6):968–975
Jasmer RM, Nahid P, Hopewell PC (2002) Clinical practice. Latent tuberculosis infection. N Engl J Med 347(23):1860–1866
Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV (2001) Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163(4):824–828
Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, Ewer K, Hill AV, Mehta A, Rodrigues C (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183(3):469–477
Andersen P, Munk ME, Pollock JM, Doherty TM (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356(9235):1099–1104
Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P (2004) Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 42(6):2379–2387
Connell TG, Curtis N, Ranganathan SC, Buttery JP (2006) Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 61(7):616–620
Dominguez J, Ruiz-Manzano J, De Souza-Galvao M, Latorre I, Mila C, Blanco S, Jimenez MA, Prat C, Lacoma A, Altet N, Ausina V (2008) Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 15(1):168–171
Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361(9364):1168–1173
Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328–1334
Goletti D, Carrara S, Butera O, Amicosante M, Ernst M, Sauzullo I, Vullo V, Cirillo D, Borroni E, Markova R, Drenska R, Dominguez J, Latorre I, Angeletti C, Navarra A, Petrosillo N, Lauria FN, Ippolito G, Migliori GB, Lange C, Girardi E (2008) Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One 3(10):e3417
Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV (2001) Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357(9273):2017–2021
Domínguez J, Latorre I, Altet N, Mateo L, De Souza-Galvao M, Ruiz-Manzano J, Ausina V (2009) Interferon-gamma-release assays to diagnose TB infection in immunocompromised individual. Expert Rev Respir Med 3(3):309–327
Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K (2005) Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 12(4):491–496
Domínguez J, De Souza-Galvao M, Ruiz-Manzano J, Latorre I, Prat C, Lacoma A, Milà C, Jiménez MA, Blanco S, Maldonado J, Altet N, Ausina V (2009) T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis 63:43–51
Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P (2011) A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 91:260–267
Lalvani A, Millington KA (2008) Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 8(2):147–152
Domínguez J, Latorre I (2008) Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents. J Crohn's Colitis 2:250–254
Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33(3):586–593
Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, Codd MB, Dodd JD, Veale D, Fitzgerald O, Bresnihan B (2010) Comparison of interferon-{gamma}-release assays and conventional screening tests before tumour necrosis factor-{alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 69:181–185
Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, Sandstede J, Frosch M, Tony HP, Kneitz C (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69(4):782–784
Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y (2009) Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb) 89(2):136–141
Girlanda S, Mantegani P, Baldissera E, Aiello P, Ratti M, Sabbadini MG, Fortis C (2010) ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol 29(10):1135–1141
Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, Kaplan M, Dogru D, Yalcin E, Pekcan S, Kose M, Topaloglu R, Besbas N, Bakkaloglu A, Kiper N (2007) Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 11(11):1177–1182
Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A (2008) Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27(10):907–913
Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, Marocco R, Lichtner M, Vullo V, Mastroianni CM (2010) Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeificiency virus infection and in patients candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 14(7):834–840
Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59(6):800–806
Takahashi H, Shigehara K, Yamamoto M, Suzuki C, Naishiro Y, Tamura Y, Hirohashi Y, Satoh N, Shijubo N, Shinomura Y, Imai K (2007) Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27(12):1143–1148
Latorre I, De Souza-Galvao M, Ruiz-Manzano J, Lacoma A, Prat C, Altet N, Ausina V, Dominguez J (2010) Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis. Eur Respir J 35:338–342
Altet N, De Souza-Galvao M, Latorre I, Milà C, Jimenez MA, Solsona J, Cantos A, Zamora JJ, Ruiz-Manzano J, Ausina V, Dominguez J (2011) Diagnosing TB infection in children: analysis of discordances using in vitro tests and tuberculin skin test. Eur Respir J 37:1166–1174
Informe sobre la situación de la tuberculosis. Red Nacional de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. España, 2010.
Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez J, García JM, Vidal R (2008) SEPAR guidelines. Diagnostic and treatment of tuberculosis. Arch Bronconeumol 44:551–566
Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159(1):15–21
Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67(1):84–90
Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ (2008) Usefulness of enzyme-linked immunospot assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 35(7):1271–1276
Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776–781
Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, Thomsen VO, Jensen DV, Koch A, Wohlfahrt J, Ravn P (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36(9):1876–1884
Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Larsen I, Ravn P (2011) Prednisolone treatment affects the performance of the QuantiFERON Gold In-Tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. doi:10.1002/ibd.21605
Greenberg JD, Reddy SM, Schloss SG, Kurucz OS, Bartlett SJ, Abramson SB, Bingham CO 3rd (2008) Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 35(5):770–775
Chee CB, Khinmar KW, Gan SH, Barkham TM, Pushparani M, Wang YT (2007) Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175(3):282–287
Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH (2010) IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect 61(2):133–143
Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME (2009) Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 36(3):546–551
Acknowledgements
We warmly thank the patients for agreeing to participate in the study. The manuscript has been revised by a native English speaker who is both a professional translator and qualified philologist from The Language Advisory & Translation Unit of the Servei de Llengües at the Universitat Autònoma de Barcelona (Spain). J. Dominguez is a researcher funded by the “Miguel Servet” programme of the Instituto de Salud Carlos III (Spain).
Disclosures
None of the investigators have any financial interest in or a financial conflict with the subject matter or materials discussed in this manuscript. This work was supported by grants from the Sociedad Española de Neumología y Cirugía Torácica, Societat Catalana de Pneumologia (SOCAP), Fundació Catalana de Pneumologia (FUCAP) and Societat Catalana de Reumatologia (SCR). None of the scientific societies nor Inverness Medical Ibérica SAU (Barcelona, Spain), Cellestis (Carnegie, Australia) or Oxford Immunotec (Abingdon, UK) had a role in the study design, implementation, data collection, management, analysis, interpretation of the data, preparation, review or approval of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mínguez, S., Latorre, I., Mateo, L. et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 31, 785–794 (2012). https://doi.org/10.1007/s10067-012-1938-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-1938-z